Bellicum Pharmaceuticals (NASDAQ:BLCM) Announces Earnings Results

Bellicum Pharmaceuticals (NASDAQ:BLCM) issued its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.04), Bloomberg Earnings reports. The firm had revenue of $1.39 million for the quarter, compared to the consensus estimate of $0.23 million. Bellicum Pharmaceuticals had a negative net margin of 6,729.02% and a negative return on equity of 123.00%.

Shares of NASDAQ BLCM traded down $0.10 during trading on Wednesday, hitting $1.14. 120,450 shares of the company traded hands, compared to its average volume of 485,114. The firm has a fifty day moving average of $1.70. Bellicum Pharmaceuticals has a fifty-two week low of $1.20 and a fifty-two week high of $7.26. The firm has a market cap of $56.43 million, a price-to-earnings ratio of -0.47 and a beta of 1.48. The company has a debt-to-equity ratio of 0.81, a current ratio of 4.74 and a quick ratio of 4.74.

Separately, ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $14.08.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.

Featured Story: Dividend

Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.